What happens when the US approves a drug that could save millions of lives?

5 325 pills are a safe, effective way to prevent, treat, or treat drug-resistant tuberculosis, according to a report from the FDA.

The drug is approved by the FDA to treat the disease in adults and to treat people with weakened immune systems.

The pills are made by a British firm, Merck, which was acquired by Pfizer in 2008.

The new drug, which will be approved for sale in July, has already been tested in people in the US and Canada.

It can be taken as a pill, taken in a liquid form, or taken in capsules, as well as injectable or intramuscularly. 

According to the FDA, the new drug works by blocking a protein known as TRFV. 

TRFV is a protein that has been linked to drug resistance and resistance to other treatments, including TDFV inhibitors. 

The TRFVs that Merck made for the pill have not shown any resistance to the new medication.

The FDA said that the pill could help about 15 million people in four countries who are vulnerable to TB, or between 2.6 and 12.7 million in the United States, and 4.3 million in other countries. 

“Our data suggest that patients with TRF-V-resistant TB should receive the drug at least three weeks prior to initiating therapy with an antibiotic to increase its efficacy and reduce side effects,” the FDA said in a statement.

“Patients with TRPV- or TRP-V2-resistant or TRPAV- and TRPA-V1-resistant TRFVT-resistant, TRFv- and/or TRPAv-resistant TDFVT- or TDFv-resistance TRPVT- resistant, TRPA v-resistant, TRP v-resistant and TRPv-dependent TB patients should be given the drug one week prior to initiation of treatment.” 

The FDA said it will be sending letters to doctors to let them know when they are likely to be eligible to take the drug. 

A spokeswoman for Pfizer, Andrea Doman, said the company is “deeply disappointed by the news.

We will continue to monitor this drug’s development and will share any additional information as it becomes available.” 

Follow NBC News Health on Facebook and Twitter, and sign up for our e-mail newsletter to get the latest health and science news. Related: